Drugs / AZD1613
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07228364 | Nov 2025 → Jan 2027 expected | autosomal dominant polycystic kidney disease | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06995820 | Jun 2025 → Sep 2026 overdue | — | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1613 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07228364 ↗ |
| Route | Subcutaneous | “SC injection” NCT06995820 ↗ |